HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 57.3%

Neg 57.3% Neu 0% Pos 0%

HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.